Shortage of Morphine Sulfate Injection: FDA Update
Areazine synthesizes this FDA drug-shortage notice directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.
Morphine Sulfate Injection is currently in shortage, with some presentations unavailable and others limited, affecting patients who rely on it for pain management.
What this FDA drug-shortage notice tells you, and what most readers miss
This notice was issued by FDA on April 7, 2026 and geographically references United States. Its severity classification of "medium" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - Drug Shortages - determines the regulatory framework behind it, which shapes what mitigations (alternative therapies, allocation timelines, manufacturer guidance) are available and which agency holds oversight.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to read it as a data point about the issuing system: how quickly FDA detected the hazard, how precise the geographic or product-identifier scope is, and whether similar notices have clustered in the same category or region in the last 90 days. Cluster patterns frequently precede a broader regulatory action, a single localized FDA drug-shortage notice is isolated; three of them within a quarter often indicate a supply-chain, infrastructure, or seasonal driver that will keep producing notices until something structural changes.
For decision-making, Areazine pairs each alert with the original agency URL, the full agency name, and a timestamp so you can verify the notice against the primary source before acting on it. Tags on this item (drug-shortage, fda, medication, Morphine Sulfate Injection) map to related alerts in the same area of risk - browsing them together gives a clearer picture than any single notice alone, because the shape of an ongoing issue only becomes visible across multiple sequential alerts.
Shortage of Morphine Sulfate Injection: FDA Update
What's in Shortage
The drug in shortage is Morphine Sulfate Injection, with generic name Morphine Sulfate Injection and brand name MORPHINE SULFATE. It is an injection dosage form and is currently in shortage status. This medication falls under the therapeutic category of Analgesia/Addiction. The shortage was first posted on 10/31/2017 and last updated on 04/02/2026.
Which Manufacturers Are Affected
Several manufacturers are impacted as follows:
- Fresenius Kabi USA, LLC: Unavailable for Morphine Sulfate Injection, 2 mg/1 mL (NDC 76045-004-11), with next release May 2026; Unavailable for 5 mg/1 mL (NDC 63323-455-01), with expected recovery TBD; Unavailable for 4 mg/1 mL (NDC 63323-454-01), with next release May 2026; Unavailable for 10 mg/1 mL (NDC 63323-451-01), with expected recovery TBD; Unavailable for 4 mg/1 mL (NDC 76045-005-11), with next release May 2026; Available for 2 mg/1 mL (NDC 63323-452-01), with advice to check wholesalers.
- Hospira, Inc., a Pfizer Company: Limited Availability for 10 mg/10 mL (1 mg/mL) (NDC 0409-3815-12), with next delivery June 2026 and estimated recovery June 2027; Limited Availability for 5 mg/10 mL (0.5 mg/mL) (NDC 0409-3814-12), with next delivery April 2026 and estimated recovery June 2026; Limited Availability for 2 mg/1 mL Syringes (NDC 0409-1890-01), with next delivery March 2026 and estimated recovery June 2026; Limited Availability for 4 mg/1 mL Syringes (NDC 0409-1891-01), with next delivery March 2026 and estimated recovery June 2026; Available for 50 mg/1 mL (NDC 0409-1896-20); Available for 50 mg/1 mL (NDC 0409-1134-05).
- Amphastar Pharmaceuticals, Inc.: Available for Morphine Sulfate Injection, 1 mg/1 mL (NDC 76329-1912-1). Contact information: Fresenius Kabi USA, LLC at 888-386-1300; Hospira, Inc., a Pfizer Company at 844-646-4398; Amphastar Pharmaceuticals, Inc. at 800-423-4136.
Why There's a Shortage
The reason for the shortage is listed as 'Other.' No specific details were provided.
What Patients Should Do
Patients who rely on this medication should speak with their pharmacist to check availability and discuss options. They may also contact the manufacturer directly for more information. Remember, patients should consult their healthcare provider before making any changes to their treatment. This article does not provide medical advice.
Source
This information is from the FDA Drug Shortage Database, with the shortage first posted on 10/31/2017 and last updated on 04/02/2026.
Original source: FDA Official Notice ↗
Related Drug Shortages
All Drug Shortages →Frequently Asked Questions
Common questions about this FDA drug-shortage notice.